Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine for negative symptoms in schizophrenia
IRCT20260609069732N1Phase 2Recruiting
- Sponsor
- University of Social Welfare and Rehabilitation Sciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Fampridine + risperidone with Placebo + risperidone (2 arms). Primary endpoint: Change in PANSS negative symptom score at week 8. Started Jul 2026; status: recruiting.
02
Drugs
dalfampridine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20260609069732N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260609069732N1.